一个远程增强程序,以减轻冠状动脉疾病患者的久坐行为:一个随机对照试验
Sophie H Kroesen1, Bram M A van Bakel1, Marijn de Bruin2
1Department of Medical BioSciences, Radboud university medical centre, Nijmegen, The Netherlands.
European journal of preventive cardiology
|March 20, 2025
概括
在心脏康复后的冠状动脉疾病患者中,一项为期3周的远程增强干预有效地减少了久坐时间,并增加了轻度体力活动. 该计划提供了一个有前途的策略,以维持身体活动的变化,超出传统的心脏康复.
科学领域:
- 心脏病学 心脏病学
- 康复医学 康复医学 康复医学
- 行为科学 行为科学
背景情况:
- 静坐时间 (ST) 是心脏康复 (CR) 后冠状动脉疾病 (CAD) 患者的一个重要问题.
- 在完成传统的CR计划后的几个月内,复发的久坐行为很常见.
- 需要新的干预措施来维持CAD患者的身体活动改善.
研究的目的:
- 评估3周远程辅助干预的有效性,旨在减少冠状动脉疾病 (CAD) 患者的静坐时间 (ST).
- 评估干预后静坐行为和体力活动 (PA) 特征的变化.
主要方法:
- 一项随机对照试验 (RCT) 涉及之前已经完成CR的CAD患者.
- 参与者被随机分配 (1:1) 接受常规护理或常规护理加上3周的远程行为改变干预.
- 主要结果:加速计衍生ST的变化;次要结果:静止行为和PA特征的变化;分析:受约束的线性混合模型.
主要成果:
- 与对照组相比,增强剂组显示ST显著减少 (-1.3小时/天) (-0.1小时/天) (p-相互作用=0.012).
- 这项干预措施导致增强组 (-1.1次/天) 与对照组 (0.2次/天) 的长时间久坐性发作显著减少 (p-相互作用<0.001).
- 轻度体力活动 (PA) 在增强剂组 (+1.1小时/天) 与对照组 (+0.2小时/天) 相比显著增加 (p-相互作用=0.030).
结论:
- 3周的远程辅助干预有效地减少了CAD患者的久坐时间,并增加了轻度的体力活动.
- 这种干预表明,除了完成标准CR程序之外,还有可能修改身体 (不) 活动行为.
- 远程干预可能为心血管疾病管理中的长期行为改变提供可扩展的解决方案.
相关概念视频
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


